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Available online 5 March 2019Background: Breast cancers show variations in the number and biological aggressiveness of cancer stem cells that
correlate with their clinico-prognostic andmolecular heterogeneity. Thus, prognostic stratiﬁcation of breast can-
cers based on cancer stem cells might help guide patient management.
Methods:We derived a 20-gene stem cell signature from the transcriptional proﬁle of normal mammary stem
cells, capable of identifying breast cancers with a homogeneous proﬁle and poor prognosis in in silico analyses.
The clinical value of this signature was assessed in a prospective-retrospective cohort of 2, 453 breast cancer pa-
tients.Models for predicting individual risk ofmetastasiswere developed from expression data of the 20 genes in
patients randomly assigned to a training set, using the ridge-penalized Cox regression, and tested in an indepen-
dent validation set.
Findings: Analyses revealed that the 20-gene stem cell signature provided prognostic information in Triple-
Negative and Luminal breast cancer patients, independently of standard clinicopathological parameters. Through
functional studies in individual tumours, we correlated the risk score assigned by the signature with the prolif-
erative and self-renewal potential of the cancer stem cell population. By retraining the 20-gene signature in Lu-
minal patients,wederived the riskmodel, StemPrintER,which predicted early and late recurrence independently
of standard prognostic factors.
Interpretation: Our ﬁndings indicate that the 20-gene stem cell signature, by its unique ability to interrogate the
biology of cancer stem cells of the primary tumour, provides a reliable estimate of metastatic risk in Triple-
Negative and Luminal breast cancer patients independently of standard clinicopathological parameters.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Metastasis1. Introduction
Tumour heterogeneity may represent a major hurdle in the clinical
management of breast cancer (BC). The identiﬁcation of molecular sub-
types of BC – Luminal-A, Luminal-B, Basal-like andHER2-positive (HER2
+) – has provided molecular foundations for the clinical and patholog-
ical heterogeneity of this disease. The integration of this new taxonomy
with traditional clinicopathological parameters has proved invaluable
for informing clinical decision-making [1].logy IRCCS, Via Ripamonti 435,
olo.diﬁore@ieo.it (P.P. Di Fiore).
. This is an open access article underOne source of phenotypic and functional heterogeneity in BC, and in
other cancers, is thought to reside in a subpopulation of tumour cells
with exclusive self-renewal and tumourigenic capacity, i.e., the cancer
stem cells (CSCs) [2,3]. The relevance of CSCs to the natural history of tu-
mours is manifold: they not only fuel the continuous growth of the can-
cer but represent also the prime suspect for its metastatic ability, and
hence adverse clinical outcome, and – in certain cases – for refractori-
ness to therapies [4–6]. It is widely believed, therefore, that advance-
ments in the understanding of the molecular and biological properties
of CSCs might beneﬁt all aspects of the management of cancer patients.
Previously, we demonstrated that a stem cell (SC)-speciﬁc transcrip-
tional proﬁle, obtained by comparing the transcriptome of normal
mammary SCs (MaSCs) with that of their progeny, could predict the bi-
ological (grade) and the molecular subtype of BCs [7]. This ﬁndingthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
The increasingly recognized relevance of cancer stem cells to
breast cancer heterogeneity argues that they might hold the key
to inform the individualized management of breast cancer pa-
tients. We searched PubMed for systematic reviews and research
articles reporting high-throughput screening, development of ge-
nomic predictors, validation of predictive and/or prognostic bio-
markers in retrospective and prospective cohort studies in breast
cancer published up to December 31, 2018, with the keywords
“breast cancer”, “genomic predictors”, multigene assays”, “cancer
stem cells”, “distant metastasis”. No publication date or language
restrictions were applied. We found that, despite the number of
putative breast cancer stemcellmarkers described in several stud-
ies, and the long purported correlation between the presence and
biological characteristics of cancer stem cells in the primary tu-
mour and clinical outcome, so far, no multigene assays able to in-
terrogate the intrinsic degree of stemness of the primary tumour is
available for the clinical management of breast cancer.
Added value of this study
Stratification of breast cancer patients for their intrinsic risk of re-
currence and for selection of the optimal therapy, while avoiding
overtreatment, demands biomarkers that rely on the underlying bi-
ology of each individual tumour. Most of existing genomic tools
for breast cancer prognostication have been developed empirically
by selecting multigene marker panels, or comparing the genomic
profiles of breast cancer specimens from patients with or without
disease recurrence. This implies that their predictive prognostic
power derives from their capacity to measure the expression of
genes at the level of the bulk tumour population. These genes
are often associatedwith the same tumour characteristics interro-
gated by the standard clinicopathological parameters, namely,
hormonal status or proliferation, thereby failing to capture the
full complexity of intra-tumoural heterogeneity. Not surprisingly,
these signatures have limited prognostic value for certain sub-
types of breast cancers, such as Triple-Negative breast cancers,
which are generally highly proliferative and hormone receptor-
negative. We report here the identification and extensive clinical
validation of a 20-gene signature that predicts risk of distant me-
tastases in patients with different breast cancer subtypes, includ-
ing Luminal and Triple-Negative breast cancers, by measuring the
intrinsic content and degree of biological aggressiveness of the
cancer stem cell population of the primary tumour. This study, to
our knowledge, is the first translational assessment combining
molecular profiling data with high-quality clinical data in the analy-
sis of a large retrospective consecutive cohort for the develop-
ment of a stem cell-based prognostic test for breast cancer. Our
results demonstrate the discovery, assessment, and clinical vali-
dation of a new multigene assay based on the biology of cancer
stem cells, which represents a novel concept in the landscape of
genomic predictors in breast cancer.
Implications of all the available evidence
Considering the increasingly recognized role of cancer stem cells
in driving tumour progression, therapy resistance and metastasis,
a prognostic model based on the molecular information captured
at the level of cancer stem cells in the primary tumour has the po-
tential to be transformative for clinical decision-making in breast
cancer, when used as a standalone test or in combination with
other genomic predictors. Based on the analysis of a large
prospective-retrospective cohort, we submit that our genomic
predictor might prove clinically valuable for the stratification of pa-
tients with negligible metastatic risk, who might safely benefit
from de-escalating regimens of chemotherapy and/or endocrine
therapy, thus avoiding overtreatment. On the other hand, this ge-
nomic tool could help identify patients at high risk of recurrence
whomight benefit frommore aggressive treatments. Additionally,
our results highlight a set of genes with a likely mechanistic role in
the metastatic process, which could represent novel molecular
targets for the development of drugs counteracting metastatic
progression of breast cancer.
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of stemness” (deﬁned as extent of molecular resemblance to normal
MaSCs), which, in turn, correlates with certain biological andmolecular
features. The “degree of stemness” most likely reﬂects the number of
CSCs within a tumour, and hence their propensity to self-renew and
proliferate. In support of this, we showed that poorly differentiated
BCs contain more CSCs (measured as tumour-initiating cells in xeno-
transplantation assays) than well-differentiated BCs [7]. Nevertheless,
direct evidence that the “degree of stemness” of a tumour is a measure
of the intrinsic content of CSCs, or of their self-renewal/proliferative be-
haviour, is lacking. Furthermore, it is not knownwhether the “degree of
stemness” of a BC is predictive of metastatic ability or clinical outcome.
If thiswere the case, it should be possible to extract from theMaSC tran-
scriptional proﬁle, robust and clinicallymanageable signatures for prog-
nostic stratiﬁcation in BC. This would add a novel dimension to our
ability to stratify BCs [8], by allowing direct and quantitative measure-
ments of the impact of subversion of the SC compartment, on the natu-
ral history and clinical outcome of a tumour. The present studies were
undertaken to investigate these possibilities.
2. Materials and methods
2.1. Study design and patients
Our study startedwith a series of in silico analyses of different public
BC datasets, which were interrogated with the set of SC-speciﬁc genes
previously identiﬁed as overexpressed in normal MaSCs vs. progenitors
[7]. These analyses resulted in the identiﬁcation and analytical valida-
tion of a 20-gene SC signature with independent predictive prognostic
power in the four different BC datasets analysed. We next assessed the
clinical relevance of the in silico ﬁndings, using a large prospective-
retrospective cohort of 2453 female BC patients with early stage, opera-
ble BC and no history of a previous malignancy, operated at the
European Institute of Oncology (IEO) in Milan between years 1997
and 2000 (the “IEO BC 97-00” cohort) (see Supplementary Methods
for details on the selection, characterization and follow-up of this co-
hort). Finally, we used a prospective consecutive series of 90 BC pa-
tients, for whom it was possible to obtain sufﬁcient amounts of fresh
biopsy tissue amenable to functional in vitro studies, to assess the corre-
lation between 20-gene SC risk score and the self-renewing prolifera-
tive behaviour of CSCs, through the execution of the serial
tumoursphere propagation assay (see Supplementary Methods for
details).
2.2. Meta-analysis of published BC datasets
For the analysis of the Ivshina, Pawitan, Loi KI, and METABRIC
datasets [9–12], original RAW data (CEL ﬁles) or processed data were
downloaded from the GEO database (Gene Expression Omnibus
http://www.ncbi.nlm.nih.gov/geo/) accession code GSE4922, GSE1456
and GSE6532 or from the cBioPortal for Cancer Genomics
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Table S1 and S2) used for the unsupervised analyses were built by
extracting, from the original datasets, information for those patients
for whom a follow-up of at least 5 years was available (Ivshina: 227 of
249 patients; Pawitan: 153 of 159 patients; Loi KI: 119 of 149 patients;
METABRIC: 1825 of 1989 patients). With the exception of the
METABRIC dataset, Affymetrix GenGhip CEL ﬁles were reprocessed
with the Affymetrix's proprietary MAS5 pre-processing algorithm, in
order to make all samples comparable with those used in the present
study. Processed ﬁles were then imported into GeneSpring GX software
version 7.3.1 (Agilent Technologies, Santa Clara, CA). According to the
GeneSpring normalization procedure, in each analysis the 50th percen-
tile of all measurements was used as a positive control, within each
hybridization array, and each measurement for each gene was divided
by this control. The bottom 10th percentile was used for background
subtraction. Among different hybridization arrays, each gene was
divided by the median of its measurements in all samples. Data were
then log transformed for subsequent analysis. All clustering analyses
were performed with GeneSpring, using the Standard Correlation as a
similarity measure and Average Linkage as a clustering algorithm for
both genes and samples. All statistical analyses were performed using
JMP 10.0 statistical software (SAS Institute, Inc).2.3. Quantitative real-time PCR analysis
Total mRNA was extracted from formalin-ﬁxed parafﬁn-embedded
(FFPE) samples and RT-qPCR reactions were performed with an
in-house custom designed TaqMan® Array. Each target was assayed in
triplicate and average Cq (AVG Cq) values were calculated and normal-
ized using four reference genes (HPRT1, GAPDH, GUSB and TBP) to
compensate for possible variations in the expression of single reference
genes and in RNA integrity due to tissue ﬁxation. Normalized data were
then processed for statistical analysis. Based on the distribution of the
reference genes, we applied the Tukey's interquartile rule for outliers
to identify poor quality RT-qPCR data [13]. After exclusion of patients
with insufﬁcient or poor quality RNA from the “IEO BC 97-00” study
cohort of 2453 patients, a total of 2316 patients were ﬁnally included
in the statistical analyses (see Supplementary Methods for details).2.4. Development of the 20-gene SC signature and of StemPrintER risk
scores
Using expression levels of the 20 SC genes obtained by RT-qPCR on
parafﬁn samples, we generated two different prognostic models:
i) the 20-gene SC signature, based on expression data of the 20 SC
genes in a training set of patients from the entire “IEO BC 97-00” cohort;
ii) StemPrintER, a Luminal BC-speciﬁc risk model, based on expression
data of the 20 SC genes in a training set from the subgroup of Luminal
BC patients. In the respective training sets, the prognostic models
were derived using the ridge penalized Cox regressionmodel, consider-
ing the normalized gene expression values of the 20 SC genes as contin-
uous covariates with log-linear effect. Cross-Validated (10-fold)
log-Likelihood (CVL)with optimization of the tuning penalty parameter
was applied. Tuning of the penalty parameter was repeated 500 times
using a different folding at each simulation and the model associated
with the highest CVL was selected [14–16]. A continuous risk score
was assigned to each patient based on the following formula: Risk
score =∑i (βi*Cqnormalized), where: i is the summation index for the
20 target genes; β is the ridge penalized Cox model coefﬁcient for
each target gene; Cqnormalized is the normalized average Cq for each
target gene. Minimum and maximum risk scores from the training set
were used to scale risk scores in a 0–100 range. For StemPrintER, the
median of the continuous risk score of the training set was used to iden-
tify two classes of risk (Low and High).2.5. Statistical analyses
In prognostic studies, primary endpoint was the cumulative inci-
dence of distant metastasis (DM), deﬁned as the time from surgery to
the appearance of a metastasis or death from BC as a ﬁrst event [17].
Local or regional recurrence, second primary cancer, death for unknown
causes or other causes were considered as competing events. Consider-
ing ﬁrst events, median follow-up for censored patients was 14·1 years
(interquartile range [IQR] 12·1–15·7). One hundred and eighty-ﬁve
(7·5%) patients were lost at 10 years of follow-up.
For the estimation of the primary endpoint, we used the Cumulative
Incidence Function (CIF), according to the methods described by
Kalbﬂeisch and Prentice [18], taking into account the competing causes
of DM.Hazard ratioswere estimated, both in the entire follow-up and in
the early (0–5 years) or late (5–10 years) time intervals, using a Cox
proportional hazards model. Multivariable models were adjusted for
Grade (G1, G2 and G3), Ki-67 (Ki-67 b 14% and Ki-67 ≥ 14%), HER2 sta-
tus (positive and negative), ER/PgR status [not expressed (Both 0) and
expressed (ER N 0 or PgR N 0)], tumour size (pT1 and pT2-3-4), number
of positive lymph nodes (pN0, pN1-2-3 and pNX) and age at surgery
(b50 and ≥ 50) (as appropriate). Subgroup analysis was performed to
investigate possible differences in the prognostic power of the risk
models in the different sub-populations. Differences in the distribution
of clinicopathological features between groups were evaluated by the
Chi-square test. Differences in the distribution of continuous risk score
between groups were evaluated using a linear regression model. A lo-
gistic regression model was used to establish association between CSC
proliferative/self-renewal phenotype and continuous risk score in the
consecutive cohort of 90 BC patients. All analyses were carried out
with the SAS software (SAS Institute, Cary, NC). All reported p-values
are two-sided.
3. Results
3.1. Identiﬁcation and in silico validation of a prognostic 20-gene SC
signature
To derive a prognostic SC-based predictor, we performed a stepwise
series of in silico analyses in published BC datasets (schematically
depicted in Fig. 1, a and b) employing the previously described panel
of genes (1059 Affymetrix probestes) that were signiﬁcantly
overexpressed between human normal MaSC vs. progenitors [7]. In
particular, we initially performed unsupervised hierarchical clustering
of the BC dataset published by Ivshina et al. [9] (described in Supple-
mentary Table S1). This allowed for the extraction, from the original
list of 1059 probesets, of a discernible panel of 329 probesets that
were highly and homogeneously expressed in a subgroup of BC patients
(Supplementary Fig. S1a). When used alone to re-clusterize BC patients
of the same dataset, this 329-probeset signature clearly distinguished
between BCs displaying a “SC-like” proﬁle (H, for High similarity to
SCs) and a “non-SC-like proﬁle (L, for Low similarity to SCs, Supplemen-
tary Fig. S1b). Interestingly, BCs displaying a high “SC-like” proﬁle
displayed worse prognosis both in univariate (HRH vs. L 2·30, 95% CI
1·50–3·59; p= 0·0001) and in multivariable analyses adjusted for all
the standard clinicopathological parameters (HRH vs. L 1·83, 95% CI
1·15–2·95; p = 0·010) (Supplementary Fig. S1c, and Supplementary
Table S1). Finally, from the 329-probeset signature, we identiﬁed amin-
imal cluster of 20 genes (henceforth, the “20-gene SC signature”) that
displayed the highest differential expression between “SC-like” vs.
“non-SC-like” BCs, and improved the independent predictive prognostic
power of the parental 329-signature in the multivariate analysis of the
Ivshina dataset (HRH vs. L 2·05, 95% CI 1·23-3·53; p=0·0054) (Supple-
mentary Fig. S1d, and Supplementary Table S1).
We validated the 20-gene SC signature in three independent BC ex-
pression datasets: the Pawitan et al. [10], the Loi et al. [11], and the
METABRIC [12] datasets. In all cases, the signature was a predictor of
Unsupervised clustering analysis of  the Ivshina et al. BC 
dataset (227 patients) using 1,059 probesets highly 
expressed in the transcriptomic profile of MaSCs
(Pece S. et al., Cell 2010)  
Identification of a signature of 329 SC genes with homoge-
neous and significantly high expression in BCs of the 
Ivshina dataset (fig. S1A) 
The 329-gene SC signature stratifies patients with poor 
vs. good prognosis  in the Ivshina dataset (fig. S1, B and C)
Identification of a minimal set of 20 genes (“20-gene SC 
signature”) that retains the prognostic power of the origi-
nal 329-gene signature in the Ivshina dataset (fig.1D) 
Pawitan et al. 
dataset
(153 patients)
Development and clini-
cal validation of a prog-
nostic model (based on 
the 20-gene signature) 
in a large retrospective 
consecutive cohort of 
BC patients
Development of the prognostic model using expression 
data from patients randomly assigned to a training set 
(772 patients)
Assessment the prognostic value of the model in an 
independent validation set (1,544 patients) 
In silico identification of 
a 20-gene SC signature 
predictive of clinical 
outcome in BC patients
a
c
Derivation of StemPrintER by retraining the original 
20-gene predictor in a training set of ER+/HER2- breast 
cancer patients (609 patients) 
Validation of StemPrintER in an independent validation 
set of ER+/HER2- patients (1,218 patients)
Validation of the 20-gene signature in 3 independent BC 
datasets (Fig. 2)
Loi/Kit et al.
dataset
(119 patients)
METABRIC
dataset
(1,825 patients)
Development and clini-
cal validation of the 
luminal BC-specific 
prognostic model 
(StemPrintER)
d
Validation of the 
prognostic value of the 
20-gene signature in 
independent public BC 
datasets
b
RT-qPCR analysis of the 20 SC genes in FFPE samples 
from ~2400 breast cancer patients
(the IEO 97-00 cohort)
Fig. 1. Schematicﬂowchart of the study design. a. Stepwise in silico analyses in the public BC dataset published by Ivshina et al. [9] that led to the identiﬁcation of a set of 20 genes (20-gene
SC signature) derived from the transcriptomic proﬁle of MaSCs with predictive prognostic power in BC. b. Analytical validation of the 20-gene SC signature in the indicated three
independent public datasets. c. Generation and clinical validation of a prognostic model (20-gene SC risk model) based on transcript expression levels of the 20 SC genes assessed by
RT-qPCR in FFPE samples from the “IEO 97–00” BC cohort. d. Development and clinical validation of the Luminal BC-speciﬁc prognostic model (StemPrintER) by retraining the original
20-gene SC risk model in Luminal ER+/HER2- BC patients.
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ters (Fig. 2; see also Supplementary Table S2 for detailed description of
the datasets and statistical analyses).
Clinical validation of the 20-gene SC signature in a prospective-
retrospective cohort study.
The clinical validity of the 20-gene SC signature was assessed using
the “IEO BC 97-00” cohort of 2453 BC patients (described in Supple-
mentary Table S3). Total mRNA was extracted from FFPE samples
and used to perform RT-qPCR reactions (see Supplementary Table S4
for the detailed list of assays). RT-qPCR expression data for the 20
SC genes, obtained from a training set of 772 cases (one-third of the
cohort), were used to develop a 20 SC gene-based risk model usinga ridge-penalized Cox regression model (Fig. 1c; see also Supplemen-
tary Table S5 for description of the algorithm). The performance of the
risk model was tested in a validation set composed of the remaining
1544 patients. The training and validation sets were balanced for
clinicopathological features and showed no difference in the average
risk score (Supplementary Table S6). In both the training and valida-
tion sets, the 20-gene SC risk model, used as a continuous variable
over the entire follow-up period, behaved as an independent predictor
of DM in a multivariable Cox regression analysis adjusted for tumour
size (pT), number of positive lymph nodes (pN), tumour grade,
Ki-67, ER/PgR or HER2 status, and age at surgery (Fig. 3a, and Supple-
mentary Table S7).
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Fig. 2.Analytical validation of the 20-gene SC signature in independent BC datasets. Left panels, Identiﬁcation of “SC-like” and “Non-SC-like” subgroups of BCs by unsupervised hierarchical
clustering analysis of the expression of the 20-gene SC signature in the BC datasets published by Pawitan et al. [10] (endpoint: disease-free survival, DFS), Loi et al. [11] (endpoint: time to
distant metastasis, DM) and in the METABRIC dataset [12] (endpoint: death from breast cancer). Right panels, Prognostic signiﬁcance of the “SC-like” (H, for High similarity to SCs) vs.
“Non-SC-like” (L, for Low similarity to SCs) classiﬁcation determined by Kaplan-Meier analysis in the same BC datasets using the endpoints speciﬁed above. Multivariable Cox
proportional hazards model (see Supplementary Table S2 for details on the multivariable analyses in the different datasets). HR*, multivariable hazard ratio; CI, conﬁdence interval; p,
p-value.
356 S. Pece et al. / EBioMedicine 42 (2019) 352–362A time-varying analysis of the validation set revealed that the signa-
ture is also an independent predictor of early (0–5 years) and late
(5–10 years) recurrence (Supplementary Fig. S2a). Furthermore, in a
stratiﬁed analysis of the validation set by BC molecular subtype, the
20-gene SC continuous risk score was an independent predictor of the
individual likelihood of developing DM in Luminal and TNBC, but not
in HER2+, subtypes (Fig. 3b, and Supplementary Table S8 for complete
analyses). Notably, compared to Luminal BCs, TNBCs showed a signiﬁ-
cantly higher average risk score (p b 0·0001), which was further signif-
icantly increased in HER2+ BCs compared to TNBCs (p b 0·0001)
(Fig. 3b, and Supplementary Fig. S2b).We submit that the lack of predic-
tive power of the 20-gene SC risk model in HER2+ BCs might reﬂect a
homogeneously distributed high “degree of stemness” in these tumourscompared to the more heterogeneous subgroups of TNBCs and Luminal
BCs.
3.2. Assessment of the biological basis of the 20-gene SC signature
We exploited the tumoursphere serial propagation assay to investi-
gate the biological bases of the 20-gene SC signature. This in vitro assay
allows for the accurate estimation of the number and degree of biolog-
ical aggressiveness of the CSCs of individual BCs [6,7], as it reﬂects the
intrinsic propensity of CSCs to continually self-renew and proliferate
(referred to as an “unlimited” phenotype) or to progressively extinguish
(“self-limiting” phenotype) over several tumoursphere generations
(Fig. 3c) (see also Supplementary Methods).
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Fig. 3. Clinical validity and biological characterization of the 20-gene SC signature. a. The 20-gene SC risk score, used as a continuous variable with a 10-unit increase (HRΔ10), predicts
distant metastasis over the entire follow-up interval in the “IEO BC 00-97” cohort. Training set, N = 772 (left); validation set, N = 1544 (right). Univariate (HR) and multivariable
(HR*) hazard ratios are in log scale. Cox proportional hazards model. Multivariable models were adjusted for standard clinicopathological parameters (see Materials and Methods).
Grey shaded areas, 95% CI. p, p-value; CI, conﬁdence interval. b. Left, Prognostic performance of the 20-gene SC continuous risk score in Luminal (N = 1213), Triple-Negative (TNBC)
(N = 143), HER2-positive (HER2+) (N = 169) BC. Right, Differences in the average 20-gene SC continuous risk score (Coef. Δ10) estimated in TNBC and HER2+ BC, relative to
Luminal BC (Ref.) in the validation set. Linear regression model. c. Left, Representative examples of tumoursphere assays displaying a self-limiting (TA-TD) or unlimited (T1-T4) CSC
self-renewal phenotype performed on primary BC biopsies. Right, Logistic regression model showing the direct correlation between the 20-gene SC risk score, used as a continuous
variable with a 10-unit increase (ORΔ10), and probability of CSCs displaying an unlimited self-renewal phenotype in the 90-BC patient cohort (Supplementary Table S9 for patients'
characteristics). Inset, distribution of tumours showing the phenotype. Odds ratio (OR) values plotted in logarithmic scale (vertical axis). Δ10, ten unit-increase; N, number of patients;
p, p-value; CI, conﬁdence interval. d. The 20-gene SC risk score, used as a continuous function as in (a) over the entire follow-up interval is an independent predictor of distant metastasis
in patients with LVI (N= 500). Multivariable Cox proportional hazards model. HR*, multivariable hazard ratio.
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358 S. Pece et al. / EBioMedicine 42 (2019) 352–362On the basis of this background, we subjected a consecutive series of
90 BC patients (described in Supplementary Table S9) to the
tumoursphere propagation assay, to investigate the correlation
between the 20-gene SC risk score and the “unlimited” vs. “self-limit-
ing” self-renewal behaviour of CSCs. We found that, for every 10-unit
increase in the risk score of the primary tumour, there was a ~2-fold in-
crease in the probability of CSCs to display an unlimited self-renewal
and proliferative phenotype, and therefore a propensity to expand in
number (Fig. 3c). These ﬁndings argue that the 20-gene SC risk model
provides a quantitative estimate of themetastatic risk of BCs by its abil-
ity to interrogate the number and biological characteristics of their CSCs.
This also corroborates the notion that, in the context of the bulk tumour
population, the metastatic potential likely resides in the subfraction of
tumour cells that display CSC characteristics (see Discussion).
In support of the clinical relevance of this idea, we found that even in
patients with lymphovascular invasion (LVI) –which is an initial critical
step in metastasis – the risk of DM augments as a function of increasing
levels of the 20-gene SC risk score (Fig. 3d). From a biological viewpoint,
this ﬁnding argues that: i) the presence of tumour emboli in the lym-
phatic and/or blood vessels of the peritumoural area is not sufﬁcient
per se to predict the occurrence of clinically-relevant metastases in BCTable 1
Correlation between the StemPrintER 2-class risk categories (Low, High) and clinicopath-
ological parameters in the Luminal validation set.
Variable ALL
N (% col)
2-class risk category p value
Low
N (% row)
High
N (% row)
All 1218 (100) 644 (52·9) 574 (47·1)
Age at surgery 0·51
b50 453 (37·2) 234 (51·7) 219 (48·3)
≥50 765 (62·8) 410 (53·6) 355 (46·4)
Histology b0·0001
Ductal 937 (76·9) 443 (47·3) 494 (52·7)
No Ductal 281 (23·1) 201 (71·5) 80 (28·5)
pT b0·0001
pT1a/b 169 (13·9) 117 (69·2) 52 (30·8)
pT1c 677 (55·6) 412 (60·9) 265 (39·1)
pT2 335 (27·5) 101 (30·1) 234 (69·9)
pT3/pT4 37 (3·0) 14 (37·8) 23 (62·2)
pN b0·0001
pN0 607 (49·8) 360 (59·3) 247 (40·7)
pN+ 579 (47·5) 267 (46·1) 312 (53·9)
pNX 32 (2·6) 17 (53·1) 15 (46·9)
Grade b0·0001
1 278 (22·8) 219 (78·8) 59 (21·2)
2 619 (50·8) 350 (56·5) 269 (43·5)
3 292 (24·0) 60 (20·5) 232 (79·5)
n/a 29 (2·4) 15 (51·7) 14 (48·3)
LVI b0·0001
Absent 852 (70·0) 495 (58·1) 357 (41·9)
Present 366 (30·0) 149 (40·7) 217 (59·3)
Ki-67 b0·0001
b14% 414 (34·0) 336 (81·2) 78 (18·8)
≥14% 803 (65·9) 307 (38·2) 496 (61·8)
n/a 1 (0·1) 1 (100) 0 (0·0)
CT/HT b0·0001
Nil 55 (4·5) 36 (65·5) 19 (34·5)
HT 514 (42·2) 322 (62·6) 192 (37·4)
CT 40 (3·3) 14 (35·0) 26 (65·0)
HT-CT 609 (50·0) 272 (44·7) 337 (55·3)
Surgery b0·0001
Quadrantectomy 1024 (84·1) 570 (55·7) 454 (44·3)
Mastectomy 194 (15·9) 74 (38·1) 120 (61·9)
Radiotherapy 0·002
No 201 (16·5) 86 (42·8) 115 (57·2)
Yes 1017 (83·5) 558 (54·9) 459 (45·1)
The association between the StemPrintER 2-class risk categories (Low, High) and the
demographic, clinical and pathological variables was evaluated with the chi-square test.
The number (N) of patients and percentage (%) in each group is indicated. pT, primary tu-
mour size; pN, nodal status; LVI, lymphovascular invasion; Ki-67, proliferation index; CT,
adjuvant chemotherapy; HT, adjuvant hormone therapy; Nil, no adjuvant therapy; n/a,
not available.patients; ii) an increased probability that LVI areas contain cells with
true metastatic potential correlates with a higher CSC burden of the
primary tumour, reﬂected in a higher 20-gene SC risk score.
3.3. Retraining the 20-signature to derive a speciﬁc genomic predictor for
luminal BC patients
In ER+/HER2- Luminal BC patients, accurate prognostication based
on the individual risk of early or late recurrence is key to tailor the use
of chemotherapy and hormonal therapy, thus avoiding under−/over-
treatment (seeDiscussion) [8,19]. To develop a genomic tool speciﬁcally
designed for metastatic risk prediction in this group of patients, we
randomly split the Luminal BC patients of the “IEO BC 97-00” cohort
(N= 1827) into a training set (one-third, N= 609), that was used to
derive a Luminal-speciﬁc risk model using the ridge penalized Cox
regression model, and a validation set (two-thirds, N = 1218)
(Fig. 1d). The two sets were balanced for clinicopathological features
(Supplementary Table S10). This approach generated a Luminal-
speciﬁc risk model that we named StemPrintER, based on its proposed
use as a SC-based genomic predictor in ER+/HER2- Luminal BCs
(Fig. 1d; see also Supplementary Table S11 and S12 for description of
the algorithm and for patient stratiﬁcation). The StemPrintER risk
score correlated with clinicopathological parameters of biological ag-
gressiveness and poor prognosis (Table 1, and Supplementary
Tables S13). Used as continuous function, StemPrintER behaved as an
independent predictor of DM over the entire follow-up interval
(Supplementary Fig. S3a, and Supplementary Table S14). Moreover, in
a time-varying analysis, the StemPrintER continuous risk score
predicted both early (0–5 years) and late (5–10 years) risk of DM in a
multivariable analysis of the validation set, adjusted for pT, pN, tumour
grade, Ki-67, and age at surgery (Fig. 4a, and Supplementary Table S15).
With the idea in mind to translate this tool into the clinical practice,
we developed a 2-class risk model, based on the median of the
StemPrintER continuous risk score in the training set (see Materials
andMethods for details), which could be used to stratify Luminal BC pa-
tients into a high vs. low risk group. The 2-class categorization further
conﬁrmed the clinical value of StemPrintER as an independent predictor
of DM in the entire follow-up (Supplementary Fig. S3b), and in the early
or late time-interval (Fig. 4, b and c). In the low risk group, the cumula-
tive incidence of distant metastasis was 2·8% before 5 years and 3·2%
between 5 and 10 years after surgery; the cumulative incidence for
the high-risk group was, respectively, 12·3% and 10·1% (Fig. 4b; see
also Supplementary Table S14 for details on univariate andmultivariate
analyses). Finally, analysis of the Luminal BC validation cohort, stratiﬁed
by clinicopathological characteristics, showed no evidence of substan-
tial heterogeneity in the predictive power of StemPrintER among the
different subgroups, regardless of whether StemPrintER was used as a
continuous function (Supplementary Table S16) or as a 2-class risk
model (Fig. 5, and Supplementary Table S17 and S18 for complete anal-
yses). However, considering the importance of the patient's lymph node
status for prognostic prediction and therapy decision-making, we note
that StemPrintER is an independent predictor of early recurrence in
lymph node-negative, and of both early and late recurrence in lymph
node-positive Luminal BC patients.
4. Discussion
The identiﬁcation and development of multigene assays for accurate
prognostication of individual BC patients has represented an expanding
area of research for more than a decade. In this context, it has become
progressively clear that biomarkers for the prediction of clinical
outcome should be able to interrogate the underlying biology of the
tumours of individual BC patients [20]. The increasingly recognized
relevance of CSCs to BC heterogeneity and disease course [5] argues
that the knowledge of the “degree of stemness” of a BC might substan-
tially advance individualized patient management. Herein, we describe
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359S. Pece et al. / EBioMedicine 42 (2019) 352–362a novel genomic predictor based on a cluster of 20 SC genes whose high
expression levels were capable of discerning a homogeneous group of
patients with adverse clinical outcome in the meta-analysis of four
distinct public breast cancer datasets. Through validation studies in alarge prospective-retrospective cohort of BC patients with high-quality
follow-up, and functional prospective studies based on the use of fresh
tumour samples from an additional consecutive series of BC patients,
we established that our 20-gene SC-based assay:
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360 S. Pece et al. / EBioMedicine 42 (2019) 352–362i) predicts the individual likelihood to develop distant metastasis in
BC, in particular in TNBC and Luminal ER+/HER2- BC cancers; ii) does
so, most likely, by interrogating the number and biological characteris-
tics of their CSCs. Of note, our genomic predictor comprises a set of
genes that do not belong (with one exception) to any other genomic
tool or molecular classiﬁer described for TNBC and Luminal BCs. Thus,
we submit that we have developed a unique tool capable of probinginto the “degree of stemness”, and hence into the clinical outcome, of
BCs.
In our efforts, we started from genes discriminating MaSCs from
progenitors in the normal gland [7]. Furthermore, we selected only
those genes that were expressed at higher levels in MaSCs vs. progeni-
tors. We did so by reasoning that: i) CSCs might display traits reminis-
cent of those present in normal MaSCs [3]; ii) since CSCs are rare, the
361S. Pece et al. / EBioMedicine 42 (2019) 352–362selection of overexpressed genes (MaSCs vs. progenitors) afforded a
higher likelihood of scoring differences, with respect to underexpressed
genes. We believe that our ﬁndings have important implications from
both the biological and clinical perspective.
From a biological viewpoint, our ﬁndings raise two connected ques-
tions: i) the relevance of the 20 SC genes to CSC phenotypes, in particu-
lar to their metastatic potential; ii) the relationship between their
expression in the normal vs. the CSC compartment.
Based on extant literature, several of the 20 genes display evident
connection to metastatic dissemination through their role in matrix
degradation, migration, invasion and engraftment (e.g. MMP1, SNF,
MIEN1, PHLDA2, EPB41L5) [21–24]. For other genes (RACGAP1,
H2AFZ, H2AFJ, APOBEC3B, CENPW, TOP2A CDK1), their implication in
the establishment of CSC phenotypes might be linked to their involve-
ment in genomic instability, which can be reasonably hypothesized
based on their role in processes, such as DNA replication and repair,
chromatin remodeling and mitotic control of chromosome segregation
[25–29]. A ﬁnal set of genes, whose putative role in metastasis is less
obvious, might be linked – directly or indirectly - to the development
of adaptive plastic responses required for CSCs towithstand and survive
in hostile environmental conditions, such as hypoxia and nutrient
deprivation, both at the primary tumour and metastatic site level, and/
or to resist hormonal or chemotherapy treatments, often in the broader
context of the activation of an epithelial-to-mesenchymal transition
(EMT) program. These genes include those involved in: i) metabolism
reprogramming and mitochondrial physiology (MRPS23, NDUFB10,
PHB) [30–32]; ii) mRNA ribonucleoparticle biogenesis, mRNA transcrip-
tion, splicing and export, and RNA processing and degradation events
(ALYREF, EXOSC4) [33–35]; iii) survival/escape from apoptosis, which
is connected to resistance to hormonal and/or chemotherapy through
hijacking of signaling pathways, such as TGF-beta and PI3K-AKT-
mTOR (NOL3, LY6E, EIF4EBP1) [36–38]. Additional evidence for amech-
anistic link between the 20 genes and the CSC phenotype comes from
the observation that these genes are frequently overexpressed in BC,
sometimes as a consequence of gene ampliﬁcation [31].
While further studies are needed to establish whether the genes of
our signature are causal in the determination and/or maintenance of
CSCs in BCs, and possibly of their metastatic potential, our observations
support the idea that CSCs are not simply reminiscent of normalMaSCs;
rather the emergence of CSC phenotypes is, directly or indirectly,
connected to the aberrant function of one or more of the 20 SC genes.
Furthermore, the ability of the 20-gene SC signature to predict DM in
TNBC and Luminal BC patients points to the existence of common
molecular workings underlying the metastatic potential of CSCs in
different BC subtypes, regardless of the molecular and phenotypic
differences that typically distinguish the different subtypes at the bulk
tumour level. In this framework, it is not surprising that, with the sole
exception of RACGAP1 (present in the Breast Cancer Index [39]) the
genes of the 20-gene SC signature are not comprised in any of the
already existing genomic predictors developed for prognostication of
Luminal BCor inmolecular classiﬁers that distinguish different subtypes
in TNBC, considering that these genomic tools are all invariably based on
the molecular proﬁle of the bulk tumour mass [40,41].
Together, our ﬁndings also support the emerging notion that the
metastatic potential of individual BCs can be traced back to themolecu-
lar characteristics of a rare subpopulation of tumour cells that display
CSC traits [42]. In this context, it is worth noting that, even in patients
with LVI, i.e., with the presence of emboli of frank tumour cells that
have already invaded lymphatic and/or blood vessels of the
peritumoural area, the likelihood of developing clinically evident DM
correlates with the CSC content of the primary tumour.
From a clinical standpoint, although future studies in independent
retrospective and/or prospective BCpatient cohorts arewarranted to in-
crease the level of clinical evidence of the reliability and transportability
of our 20-gene SC-based genomic tool, our results might have immedi-
ate relevance to the clinical management of BC patients, in particular forthe subgroup of ER+/HER2- Luminal BC patients. These patients
represent themajority (~75%) of the cases [43] and display high molec-
ular heterogeneity and variability in their clinical behaviour. Therefore,
Luminal BC patients can greatly beneﬁt from accurate stratiﬁcation of
their risk of recurrence, for the administration of the optimal therapy,
while avoiding under- or over-treatment [19,44]. In this direction, we
developed - based on the 20-gene SC signature - StemPrintER, a speciﬁc
risk model for Luminal BC. StemPrintER is an independent predictor of
both early and late metastasis. This places StemPrintER among the
more recently developed second generation multi-gene assays, such
as Prosigna [45], BCI [39], and EndoPredict [46], which have
been shown to outperform ﬁrst generation BC prognostic tests -
e.g., Oncotype DX [47] and Mammaprint [48] - in the prediction of the
risk of late recurrence (5–10 years post-surgery). In particular,
StemPrintER predicts early metastasis in lymph node-negative BC
patients, and both early and late metastasis in lymph node-positive BC
patients. StemPrintER could therefore ﬁnd clinical application as a tool
to tailor the administration of adjuvant chemotherapy, in addition to
the standard endocrine therapy, in those Luminal BC patients at high
risk of early recurrence, while sparing unnecessary chemotherapy to
low risk patients [19].
On the other hand, StemPrintER could also represent a valuable tool
to identify Luminal BC patients at high risk of late recurrence, who
might beneﬁt from prolongation of endocrine therapy beyond the stan-
dard 5 years of treatment. This is an important question in the clinical
management of ER+/HER2- Luminal BC patients who remain at persis-
tent risk of recurrence for at least 15–20 years [49], with N50% of
relapses and more than two-thirds of deaths occurring N5 years after
the original diagnosis. However, while continuation of endocrine ther-
apy reduces the proclivity to develop late recurrences [50], its beneﬁts
must be weighed against side effects and quality of life, avoiding over-
treatment through accurate patient stratiﬁcation.
We therefore submit that, by its unique ability to interrogate the
“stemness” of individual BCs, StemPrintER might prove clinically valu-
able, either as a standalone test or in combination with other genomic
predictors or clinicopathological parameters, to guide individualized
clinical decision-making in Luminal BC patients.
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